Vertex reportedly raised its full-year 2026 revenue guidance after strong third-quarter results. The report does not state the revised guidance or the size of the increase. It links the outlook to growth beyond Vertex’s core cystic fibrosis products.
Key facts
Vertex raised its full-year 2026 revenue guidance following strong third-quarter results. source
Increased acquisition and commercialization costs are impacting Vertex's GAAP earnings. source